NVAC Overview

Clinical Trial Presentation: Profusa, Inc. will present an abstract on their Lumee™ Oxygen tissue monitoring platform at the Paris Vascular Insights (PVI) 2025 conference, focusing on its application in patients with Peripheral Arterial Disease (PAD).

Innovative Technology: The Lumee technology allows for continuous, real-time measurement of tissue oxygen levels within the body, representing a significant advancement in biochemistry monitoring for both clinical and home use.

Company Overview: Profusa is a digital health company based in Berkeley, California, dedicated to developing tissue-integrated sensors that provide actionable medical data, aiming to enhance personalized healthcare.

Forward-Looking Statements: The press release includes forward-looking statements regarding Profusa's future performance and potential risks, emphasizing the uncertainty surrounding these projections.

Leadership Changes at Profusa: Profusa, Inc. has appointed Peter O’Rourke as lead independent director and Fred Knechtel as Chief Financial Officer following its merger with NorthView Acquisition Corp.

Experience of New Board Members: O’Rourke brings extensive experience from his role as Acting U.S. Secretary of Veterans Affairs, while Knechtel has a strong background in finance and operations across various industries including life sciences and consumer products.

Focus on Biosensor Technology: The company aims to advance its innovative biosensor platform that continuously monitors individual biochemistry, which is expected to transform health monitoring.

Forward-Looking Statements Caution: The announcement includes forward-looking statements regarding the company's future performance, highlighting inherent risks and uncertainties associated with such projections.

Delisting Announcement: NorthView Acquisition (NVAC) will be delisted from Nasdaq due to failure to complete its initial business combination by the deadline of December 20, resulting in trading suspension effective December 27.

No Appeal Filed: The company has chosen not to appeal Nasdaq's decision regarding the delisting of its securities.

Compliance Notice from Nasdaq: NorthView Acquisition (NVAC) has been notified by Nasdaq of non-compliance with Listing Rule 5250(c) due to the failure to file its Form 10-Q for the period ending September 30, although this does not immediately affect its share listing.

Future Compliance Plans: The company plans to file the required Form 10-Q within 60 days to avoid delisting and eliminate the need for a formal compliance plan.